anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Sexually transmitted infection rates continue to rise in adolescents and young adults. Treatment of patients and their partners is vitally important to prevent reinfection and morbidity. Expedited partner therapy (EPT) is a legally available option for clinicians. EPT is endorsed by the Centers for Disease Control and Prevention and allows clinicians to prescribe medication for certain STIs for their patients' partner(s) without an evaluation of the partner(s). However, EPT is underutilized, and multisystem-level barriers exist to successful EPT exist. This article reviews the indications of EPT, common barriers to EPT and solutions to overcome these barriers, and practical considerations when prescribing EPT.
A system for health services is provided. When a provider partners with the system the provider is assisted with the creation of an introduction video explaining their practice. The provider may also be assisted in the creation of videos that correspond to the top conditions or diseases treated by the provider as well as the top medicines that are prescribed. When a patient schedules a health service, the patient is initially provided the introduction video for the provider. During the health service, the system collects the health data entered or spoken by the provider. Based on the monitored data, the system automatically recommends relevant videos or content that may be included in a report for the patient. After the health service is completed, the system may further assist the provider in creating a video that explains the diagnosis and recommended treatment regiments.
PURPOSE: There have been limited studies examining the prospective association between the Systemic Immune-Inflammation Index (SII), a novel inflammatory marker, and mortality among individuals with diabetes in the United States.
METHODS: We utilized data from the National Health and Nutrition Examination Survey (NHANES), a representative sample of US adults, linked with information from the National Death Index.
RESULTS: Our study included 8697 individuals from NHANES spanning the years 1999 to 2018. SII was calculated by dividing the platelet count by the neutrophil count and then dividing that result by the lymphocyte count. We employed multivariable Cox proportional hazards regression analysis to investigate the associations between SII levels and all-cause as well as cause-specific mortality, while adjusting for potential confounding factors. SII levels were categorized into quartiles based on the study population distribution. Over a median follow-up period of 94.8 months (with a maximum of 249 months), we observed a total of 2465 all-cause deaths, 853 deaths from cardiovascular causes, 424 deaths from cancer, and 88 deaths related to chronic kidney disease. After adjusting for multiple variables, higher SII levels were significantly and non-linearly associated with an increased risk of all-cause mortality in Quartile 4 (HR 1.74, 95% CI 1.15-2.63, P for trend = 0.043) when Quartile 1 was used as the reference group. Additionally, we identified a linear association between SII and cardiovascular mortality, with a 70% higher risk of cardiovascular mortality in Quartile 4 (HR 1.70, 95% CI 1.18-3.30, P for trend = 0.041) compared to Quartile 1.
CONCLUSION: Our findings indicate that SII is significantly associated with an elevated risk of all-cause and cardiovascular mortality in US adults with diabetes.
Participants will receive N-803 1 mg subcutaneously (SC), PD-L1 t-haNK (\~2 × 10\^9 cells/infusion) intravenously (IV), and Bevacizumab (10 mg/kg IV) combination therapy during 28-day cycles on days 1 and 15 of each cycle. Maximum treatment period is 76 weeks, 19 cycles.
Cognitive deficits are a strong predictor of functional outcome in schizophrenia, yet poorly remediated by current treatments. Disturbances in dorsolateral prefrontal cortex (DLPFC) function underlie core impairments such as in cognitive control and thus represent a critical target for novel therapeutics. Initial studies indicate transcranial direct-current stimulation (tDCS) may be effective in reducing symptoms due to DLPFC dysfunction. While tDCS potentially represents an exciting, novel therapeutic advance, a number of basic questions should be addressed prior to conducting larger-scale clinical trials, including: verifying therapeutic target engagement, optimizing treatment parameters, and evaluating for meaningful clinical effects. Recent studies employing tDCS to enhance prefrontal cortical function in schizophrenia applied stimulating electrodes over the left frontal scalp region, putatively targeting the left DLPFC. However, explicit confirmation of such target engagement is lacking. Further, EEG studies have demonstrated close links of frontal cortical gamma oscillations to cognitive control processes but modulation of this critical physiologic process has not been investigated. Accordingly, the primary aim of this study is to employ multimodal imaging to explicitly test for the assumed DLPFC engagement (fMRI) and modulation of frontal gamma activity (EEG) by tDCS. This study will also investigate the optimization of tDCS application parameters. Analogous to dose-finding investigations in drug studies, we will conduct a parametric investigation of optimal current strengths. Also, while there is extensive evidence for tolerability of single session tDCS, confirmation of feasibility of multisession optimized protocols in schizophrenia is lacking and so will be explicitly evaluated.

In summary, a successful outcome of this study would provide tDCS the sound mechanistic and methodologic basis for more definitive testing in large-scale clinical trials as a highly innovative therapeutic intervention for cognitive impairments in schizophrenia.
Bilateral trismus associated with oral cancer was commonly occurred in those who had received surgical intervention and radiotherapy. Complete release of bilateral fibrotic tissues followed by free flaps reconstruction was the main current surgical intervention. However, reconstructions of both defects mostly needed to harvest two flaps from different donor sites were time-consuming and increasing morbidities. Herein, we presented three cases who undergone modified reconstructive method by harvesting the anterolateral thigh (ALT) flap and tensor fascia latae (TFL) flap simultaneously from the same donor site. Trismus release was performed including resection of the buccal part and fibrotic tissue, myotomy of the masticatory and medial pterygoid muscles, and bilateral coronoidectomy. Case 1, a 52 years-old man, with severe trismus as the interincisal distance (IID) was about 0 mm. He undergone a combined 12 × 7.5 cm ALT and 11 × 6 cm TFL flap reconstruction from a single-donor thigh. The IID apparently increased to 37 mm after 1-year follow-up. Case 2, a 64 years-old man, went through a combination of 6 × 7 cm ALT and 6 × 6 cm TFL flap reconstruction from unilateral thigh for severe trismus. The IID significantly improved from 10 mm to 30 mm after one and a half-year follow-up. Case 3, a 53 years-old woman, with IID was around 0 mm before the surgery. A combined 9 × 3 cm ALT and 9 × 3 cm TFL flap reconstruction was performed as the IID enhanced to 20 mm after 6 months follow-up. This reconstruction method using ALT and TFL flaps harvested from a single-donor thigh simultaneously could be suitable for patients with bilateral severe trismus.
INTRODUCTION: Among the different options for varicocele surgery, microsurgical varicocelectomy demonstrates the best results, but a relapse is subsequently detected in 1-3% of cases. It was previously believed that the cause of recurrence lies in the presence of various sources of venous outflow from the testicle, but recent studies show that the collaterals of the gonadal vein are the main reason of recurrence.
PURPOSE OF THE STUDY: to determine the leading cause of recurrence, to evaluate the effectiveness and optimal surgical tactics depending on the method of primary treatment.
MATERIALS AND METHODS: Surgical treatment of 74 patients with recurrent varicocele was performed for 5 years. Depending on the method of primary treatment, two groups were formed: 1 - relapse after non-microsurgical varicocelectomy (n=37), 2 - relapse after microsurgical varicocelectomy (n=37). Patients of the first group underwent microsurgical subinguinal varicocelectomy. Patients of the second group underwent endovascular surgery or redo microsurgical varicocelectomy.
RESULTS: 1 group. Scrotal pain syndrome was relieved in 90% of cases (n=18). Among patients with complaints of infertility (n=8), natural pregnancy occurred in 57,1% (n=4). An improvement in sperm parameters was found among 18 (75%) patients with pathospermia. The US-recurrence rate was 5.4% (n=2), clinical manifestation revealed in 1 case (2,7%). Intraoperatively, preserved branches of the gonadal vein were detected in all cases. 2 group. Scrotal pain syndrome was relieved in 95,8% of cases (n=23). Among patients with complaints of infertility (n=11), natural pregnancy occurred in 27,3% (n=3). An improvement in sperm parameters was found among 14 (73,7%) patients with pathospermia. The US recurrence rate after repeated microsurgery was 13% (n=3), after endovascular intervention - 38.5% (n=5). Clinical manifestation and indications for reoperation were identified in one patient who underwent endovascular embolization. Other cases of the second recurrence were subclinical, no indications for surgical treatment were identified. Renospermatic reflux was determined in all cases of phlebographic recurrence confirmation. No patients with ileospermatic reflux, as well as May-Turner syndrome, were identified. In 8 cases of phlebography, there was no technical possibility to perform embolization; in 3 patients, recurrence was not confirmed. Always the intact gonadal vein branches were identified mainly in the immediate vicinity of the testicular artery, in case of repeated microsurgical operation. There were no cases of testicular atrophy or postoperative hydrocele in any of the groups.
CONCLUSION: Missing collaterals from the gonadal vein basin play a key role in the genesis of varicocele recurrence. When choosing a surgical treatment option for patients with recurrent varicocele, it is necessary to take into account the method of primary treatment. The main factor to minimize the recurrence risk is the obligatory using of microsurgical techniques and a thorough revision of the spermatic cord components during the primary operation.
Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the cough center. In excessive doses, hydrocodone, like other opium derivatives, will depress respiration. The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Hydrocodone can produce miosis, euphoria, and physical and psychological dependence. 

Chlorpheniramine is an antihistamine drug (H1 receptor antagonist) that also possesses anticholinergic and sedative activity. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa. 

Hydrocodone release from hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is controlled by an extended-release drug delivery system, which combines an ion-exchange polymer matrix with a diffusion rate-limiting permeable coating. Chlorpheniramine release is prolonged by use of an ion-exchange polymer system. 

Following multiple dosing with hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension, hydrocodone mean (S.D.) peak plasma concentrations of 22.8 (5.9) ng/mL occurred at 3.4 hours. Chlorpheniramine mean (S.D.) peak plasma concentrations of 58.4 (14.7) ng/mL occurred at 6.3 hours following multiple dosing. Peak plasma levels obtained with an immediate-release syrup occurred at approximately 1.5 hours for hydrocodone and 2.8 hours for chlorpheniramine. The plasma half-lives of hydrocodone and chlorpheniramine have been reported to be approximately 4 and 16 hours, respectively.
The invention relates to an immunomodulating synbiotic composition, in particular a probiotic bacterial composition, further enriched with a prebiotic and biologically active substances that have a beneficial effect on human health in the prevention and/or therapy of inflammatory and immune diseases in gastrointestinal tract, including symptoms of intestinal dysbiosis and inflammatory bowel syndrome. In particular, the composition comprises the probiotic component of living cells of a biologically pure culture of a bacterial strain selected from the group of Lactobacillus delbrueckii subsp. bulgaricus LBB-06-НБПМК 8918, Lactobacillus helveticus LLH-108-НБПМК 8760, Lactobacillus acidophilus LLA-10-НБПМК 8242, Lactobacillus rhamnosus LLR-L1-НБПМК 8769 и Lactobacillus fermentum LLF-01-НБПМК 8781 or combinations thereof, prebiotic-arabinogalactan and colostrum. The used lactic acid bacteria strains are selected so that in combination with each other and in combination with the other components - the prebiotic and the colostrum, they give high survival, achieve the specific probiotic effect and the guaranteed antimicrobial activity against human pathogens, as adhesive and immunomodulating properties of the composition. The indigestible dietary fiber of arabinogalactan, thanks to its immunomodulating (antivirus and antitumor) activity, combined in the synbiotic formula, form a protective layer around probiotics and control their release into the intestinal tract. The enriched multifunctional formula of the synbiotic composition according to the invention, including proline polypeptides rich (4.5%) and IgG (minimum 20%) colostrum content, supplies the necessary immune, growth factors and a balanced combination of vitamins and minerals. The orally administered synbiotic composition demonstrates an immunomodulating effect, shown in an increase in % of activated NK (natural killer) cells in the peripheral blood and a decrease in the levels of anti-inflammatory cytokines in fecal samples, and in patients with irritable bowel syndrome (IBS) in reduction of faecal calprotectin to a reduction or even disappearance of clinical symptomatology.
FIELD: medicine. SUBSTANCE: the present innovation deals with pharmaceutical technology for obtaining medicinal preparations out of animal-originated raw material. Liver of dog fish shark should be homogenized, degreased due to cold sedimentation at 1-5 C for 20-24 h. Then degreased homogenate is directed for thermal and chemical protein coagulation for 5-6 h to obtain stabilized extract to be ampulated and autoclaved after centrifuging and membranous filtration. The present innovation enables to achieve stabilization of biologically active organopreparation, maximum extraction of cellular juice and development qualitative medicinal preparation out of dog fish shark at more prolonged expiry terms to be applied in complex methods of prophylaxis, treatment and rehabilitation in case of different types of prostatic pathology and as an adjuvant in oncological practice. EFFECT: higher efficiency. 1 dwg, 1 ex
BACKGROUND: Existing researches have predominantly focused on the implications of dynamic alterations in the triglyceride-glucose (TyG) index and traditional obesity measures for cardiovascular disease (CVD) risk. However, the application of the weight-adjusted waist index (WWI), which incorporates the dynamically changing body composition factors of weight and waist circumference, alongside the TyG index for predicting CVD risk, remains unexplored. This study explores the relationships between baseline TyG-WWI index and its dynamic changes with CVD risk.
METHODS: Subjects were drawn from the China Health and Retirement Longitudinal Study. Logistic regression analyses were conducted to determine the relationships between baseline and longitudinal changes in the TyG-WWI index and CVD risk, quantified through odds ratios (ORs) and 95% confidence intervals (CIs). The robustness of results was confirmed via subgroup analyses and E-values. Additionally, restricted cubic spline and quartile-based methods evaluated the relationships between baseline and cumulative TyG-WWI indices and CVD risk.
RESULTS: Over two survey waves, 613 CVD events were recorded. Analysis using adjusted multivariable models demonstrated a significant relationship between the cumulative TyG-WWI index and increased CVD risk, with an adjusted OR (95% CI) of 1.005 (1.000, 1.009). Class 2 of the TyG-WWI index change showed greater risk of CVD compared to Class 1, with ORs of 1.270 (1.008, 1.605). However, no significant connection was observed between the baseline TyG-WWI index and CVD risk (OR = 1.007, 95% CI: 0.996, 1.019). These findings were corroborated through extensive sensitivity analyses.
PURPOSE: An infectious bronchitis(IB) virus K40/09 strain and a vaccine using the same are provided to effectively prevent novel mutant type IB and to prevent IB in a domestic chicken. CONSTITUTION: An infectious bronchitis(IB) virus K40-09 strain (deposit number KCTC 11937BP) is isolated from domestic poultry. A vaccine for preventing poultry from diseases caused by IB viral infection contains the IB virus and a pharmaceutically acceptable carrier or diluent. The virus is an attenuated or inactivated virus. The vaccine additionally contains an adjuvant and one or more vaccine ingredients for infectious other pathogen. A method for controlling the diseases caused by IB viral infection comprises a step of administering the virus to birds. A method for manufacturing the IB virus comprises: a step of inoculating to IB virus to a substrate which is susceptible to infection; a step of proliferating the IB virus; and a step of collecting materials containing the IB virus. The substrate is an embryonic egg. [Reference numerals] (AA) Aggressive vaccination group; (BB) Negative control group; (CC) Spawning rate(5%); (DD) K40/09 week aggressive vaccination; (EE) Days after aggressive vaccination
Twelve habitual breakfast consumers with type 2 diabetes (T2D) were recruited for the study. They completed two, 7-day conditions in random order with a minimum of a 7-day washout period between study days. They consumed either a high protein (PRO) or high carbohydrate (CHO) breakfast for 6 days of acclimatization, and on the seventh day, they reported to the lab at 0700 hours following a \~12 hour overnight fast and underwent forearm catheterization before a baseline blood draw. The participants consumed the respective breakfast at \~0730 hours. Four hours post-breakfast, subjects consumed a standard lunch meal. Blood samples were taken continuously throughout the 8-hour test day.
An AET intervention is designed to increase the aerobic fitness levels of IBD sufferers through daily activity, which is notably lower in this population and could be beneficial for sufferers managing this lifelong disease. With an increase in physical activity, the exergame aims to introduce, instill and integrate daily physical activity in the lives of IBD sufferers. The Just Dance Kids exergame for Nintendo Wii employs moderate intensity physical activity and is well suited for this study. The exergame intervention protocol will comprise a ramped duration aerobic exercise training starting with 10 minutes in week 1 and rises to 30 minutes per session in weeks 5 through 8. Just Dance Kids will be used by participants under the age of 11 and Just Dance for participants over the age of 10 due to the age appropriate dancing skill required in each game. The aim is to determine if this moderate intensity, 5 times per week exercise could decrease IBD flare-ups, improve cardiovascular fitness, reduce depressive symptoms, improve quality and quantity of sleep and improve the health-related quality of life in children and adolescents with IBD.
A direct polycondensation method for medical biodegradable polylactic acid (PLA). The invention uses commercialized creatinine (a type of biomaterial organic guanidine compounds—the arginine metabolite creatinine in human body) as the catalyst and industrial lactic acid (mass content 85-90%, aqueous solution) as the monomer to synthesize the PLA in terms of second polycondensation without solvent. Instead of tin catalysts having cytotoxicity, the catalyst used in the invention has high biocompatibility and biosafety. The synthesized PLA does not contain any metal and other toxic components; therefore, it can be used as the carrier for targeting drugs and controlled release drugs. The green catalyst and green processing method (no solvent applied and no toxic products produced) are used to synthesize the green biodegradable PLA with high biosafety. The molecular weight distribution for all synthesized products is narrow and the molecular weight is controllable within 1.5-3.0×10 4 .
Women with type 2 diabetes (n=90) experiencing ≥1 storage lower urinary tract symptoms and poor sleep health will be recruited from the outpatient departments or wards/units of the selected hospitals/clinics. Our study aims to examine the effects of conservative management incorporating urologic health promotion and sleep health promotion on relieving storage lower urinary tract symptoms and poor sleep, and on improving urologic health self-management behaviors and health-related quality of life. Women who agree to participate will be randomly assigned into the intervention group A, intervention group B, or comparison group. The intervention group A receives a 4-month conservative management with sleep hygiene related adjustments, pelvic floor muscle training, and urologic health promotion. The intervention group B receives a 4-month conservative management with brief behavioral treatment for insomnia (BBTI), pelvic floor muscle training, and urologic health promotion. The comparison group receives information related to pelvic floor muscle training and urologic health promotion, and receives a brief conservative management related to sleep hygiene adjustments after the completion of data collection. Information related to intervention effects is obtained by a questionnaire, a wristwatch-like actigraphy, and physical activity/diet/voiding/sleep logs from all participants at 4 data collection points: baseline, and 2-, 4-, 6-month follow-ups. Our study hypothesis is that the intervention effects on relieving storage lower urinary tract symptoms and poor sleep, and on improving urologic health self-management behaviors and health-related quality of life in the intervention group A or B are superior to the changes revealed in the comparison group. The effects of the provided intervention on storage lower urinary tract symptoms, sleep quality, urologic health self-management behaviors, and health-related quality of life will be examined by Generalized Estimating Equations procedures with the estimations of effect sizes. Results of Chi-squared tests and descriptive statistics will also be used to present the intervention effects.
New therapeutic compsn. comprises camylofin noramidopyrin mesylate (Avapyrazone), sodium noramidopyrin mesylate monohydrate, chlormezanone and meprobamate, specifically in the ratio of 60 mg:210 mg:50 mg:50 mg respectively. Used as synergistic mixt. the compsn. has muscle relaxant, anxiolytic, analgesic and antiinflammatory activity and is esp. useful in treating pain and spasm of smooth muscle e.g. in gastrointestinal tract, of striated muscle, and of joints. A pref. dosage unit contg. 60 mg of camylofin noramidopyrin mesylate (Avapyrazone) 210 mg of sodium noramidopyrin mesylate monohydrate, 50 mg of chlormezanone and 50 mg of meprobamate, was given to adults at up to 6 dosage units daily.
Patients will receive at first the Labyrinth training for 10 sessions of 45 minutes, delivered 4 days per week. The, they will undergo the Standard training for 10 sessions of 45 minutes, for around 4 days per week. Before and after each training patients are tested for primary and secondary outcomes with standardized tests.